<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603302</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT02603302</nct_id>
  </id_info>
  <brief_title>Radiation Dose Escalation in Locally Advanced Rectal Cancer</brief_title>
  <acronym>RaDE</acronym>
  <official_title>Phase II Study of Neoadjuvant Radiotherapy Dose Escalation in Association With Chemotherapy for the Treatment of Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Brasilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Brasilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a one arm study where patients with locally advanced rectal cancer will receive
      neoadjuvant treatment with escalated dose radiotherapy (with 3D conformal radiotherapy, up to
      59,4 Gy) and radiosensitizing chemotherapy. Then, patients will operated (total mesorectal
      excision) after 8 weeks of interval. Primary endpoint will be pCR (pathologic complete
      response).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Rectal cancer is a highly prevalent disease all over the world. In Brazil, it is the second
      most common cancer among women (after breast tumors), with an estimated incidence of 17.2
      cases per 100,000 inhabitants and is the third most common cancer in men (after prostate and
      lung cancers), with an estimated incidence of 15.4 cases per 100,000 inhabitants.

      Goals:

      The aim of this study is to evaluate the pathologic complete response (pCR) of patients with
      locally advanced rectal cancer (LARC) treated with neoadjuvant radiochemotherapy (RCT)
      employing anticancer drugs at standard dose and interval extended to surgery with or without
      adjuvant neoplastic therapy.

      Procedures:

      Neoadjuvant chemoradiotherapy with radiation dose escalation associated with radiosensitizing
      therapy and surgery with a total mesorectal excision (TME), 8 weeks after completing
      neoadjuvant treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Pathologic evaluation of the surgical specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Locally advanced rectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU
Surgery 8 weeks after the neoadjvuant treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dose Escalation Radiotherapy</intervention_name>
    <description>RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU</description>
    <arm_group_label>Locally advanced rectal cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Delayed surgery</intervention_name>
    <description>Surgery after 8 weeks with TME (total mesorectal excision)</description>
    <arm_group_label>Locally advanced rectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced rectal cancer, 0-15 cm from anal verge, cT3/4 or cN+

        Exclusion Criteria:

          -  Metastatic disease, previous chemotherapy, previous radiotherapy, previous malignant
             non-skin tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos Santos, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Brasília University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcos Santos, MD PhD</last_name>
    <phone>+ 55 61 83554308</phone>
    <email>marcosrxt@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brasilia Univeristy Hospital</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <zip>7676105</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcos Santos, MD PHD</last_name>
      <phone>+55 61 83554308</phone>
      <email>marcosrxt@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <last_update_submitted>June 11, 2016</last_update_submitted>
  <last_update_submitted_qc>June 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Brasilia</investigator_affiliation>
    <investigator_full_name>Marcos Santos</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>escalated dose</keyword>
  <keyword>interval</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We may share data in requested by metanalists</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

